Paraxanthine (1,7-Dimethylxanthine · Caffeine Primary Metabolite · Cognitive Performance · enfinity®)

Compound	Paraxanthine (1,7-Dimethylxanthine)
Chemical class	Alkaloid — Purine (Dimethylxanthine; primary caffeine metabolite)
CAS	611-59-6
Primary source	Not plant-derived directly — primary metabolite of caffeine via hepatic CYP1A2; trace in coffee
Key applications	Caffeine’s primary active metabolite; lipolytic; cognitive performance; athletic endurance; emerging supplement ingredient
Claim strength	Moderate
Typical form	Paraxanthine isolate (emerging commercial ingredient); synthetic; also minor coffee constituent
Buy from Herbuno	Request availability and bulk pricing →

Name origin: Para- (Greek: beside, next to) + xanthine (from Greek xanthos = yellow; xanthine is a yellow crystalline compound) — referring to its position as the 1,7-isomer (versus theophylline = 1,3-dimethylxanthine and theobromine = 3,7-dimethylxanthine). Paraxanthine (1,7-dimethylxanthine, PXN) is the primary metabolite of caffeine in humans — approximately 84% of ingested caffeine is metabolised to paraxanthine via CYP1A2 in the liver (the remaining ~12% to theobromine and ~4% to theophylline). Paraxanthine has long been considered the primary active form responsible for many of caffeine’s physiological effects, but the research has primarily studied caffeine (the parent compound) rather than paraxanthine directly. Commercial development: Paraxanthine has recently attracted significant commercial attention as a standalone supplement ingredient. Trademarked as enfinity® (Natural Alternatives International) and Purolife® (Compound Solutions), paraxanthine is being positioned as a “caffeine alternative” with faster onset, shorter duration, fewer side effects (less jitteriness, anxiety, heart rate increase), and no crash — claims that require independent validation but have growing research support. Mechanism: Like caffeine, paraxanthine is an adenosine receptor antagonist (A1, A2A) and PDE inhibitor, but with different receptor affinity profile from caffeine. Paraxanthine has relatively greater A2A antagonism and higher lipolytic potency than caffeine. Critically, paraxanthine does not convert to other metabolites (it is a terminal metabolite) and has a shorter half-life than caffeine (~3.5 hours vs caffeine’s 5–6 hours), producing a faster but shorter stimulation profile. Commercial source: Not currently in the Herbuno catalogue. Contact Herbuno for availability assessment.

---

Evidence for Paraxanthine Applications

Cognitive performance and alertness: A recent double-blind RCT (Yoo et al., 2021, Nutrients, n=40) found paraxanthine 200 mg superior to placebo and comparable to caffeine 200 mg for cognitive performance (reaction time, sustained attention, executive function) but with significantly lower scores for jitteriness, anxiety, and heart rate increase than caffeine. This is the foundational human clinical study establishing paraxanthine’s cognitive profile. Claim strength: Moderate (single RCT; replication needed).

Lipolytic and fat metabolism: Paraxanthine is reported to have greater lipolytic potency than caffeine at equivalent doses (higher free fatty acid mobilisation from adipocytes). This has been claimed as a weight management advantage, though the clinical significance of the lipolytic difference vs caffeine in achieving fat loss outcomes has not been demonstrated in longer-term trials. Claim strength: Emerging.

Athletic performance: One RCT (Yoo et al., 2023) showed paraxanthine 200 mg improved bench press and reaction time performance vs placebo, with comparable effects to caffeine but lower cardiovascular side effects. Claim strength: Moderate (limited RCTs).

---

Frequently Asked Questions — Paraxanthine

If paraxanthine is caffeine’s main metabolite, why not just take caffeine?
Caffeine is a prodrug that yields paraxanthine (84%), theobromine (12%), and theophylline (4%) in different individuals at different rates depending on CYP1A2 activity. CYP1A2 is highly polymorphic — ultra-rapid metabolisers convert caffeine to paraxanthine very quickly (faster onset, shorter duration), while slow metabolisers have prolonged caffeine effects with more side effects and slower paraxanthine formation. Direct paraxanthine supplementation bypasses this metabolic variability, providing more predictable pharmacokinetics regardless of CYP1A2 genotype. This pharmacogenetic argument is paraxanthine’s primary differentiation claim from caffeine.

Does paraxanthine have fewer side effects than caffeine?
The emerging evidence suggests yes — but the evidence base is limited. Caffeine’s side effects (jitteriness, anxiety, tachycardia, insomnia, GI distress) are partly mediated by the non-paraxanthine metabolites (theophylline at A1 receptor; theobromine at A2B receptor) and partly by caffeine’s broader receptor profile vs paraxanthine. The Yoo et al. 2021 RCT found significantly lower jitteriness and anxiety scores with paraxanthine 200 mg vs caffeine 200 mg. Larger trials with pre-specified safety outcomes are needed to confirm the superior tolerability profile.

What is the regulatory status of paraxanthine as a supplement?
Paraxanthine is not currently GRAS in the US (unlike caffeine, which is GRAS for food uses). It is sold as a dietary supplement ingredient in the US under DSHEA (as a “new dietary ingredient” or “constituent of a natural substance” framing). Regulatory agencies have not specifically evaluated paraxanthine as a standalone ingredient — its novelty as a supplement (primarily available from 2022 onwards) means it lacks the safety database of caffeine. EU Novel Food assessment would likely be required before marketing as a food supplement in Europe.

Is paraxanthine in coffee or tea naturally?
Paraxanthine is present in trace amounts in brewed coffee and tea as a minor metabolite that forms during roasting and brewing — at concentrations far below pharmacological thresholds (typically <0.1 mg per cup). The paraxanthine you produce from drinking coffee is endogenously generated in the liver, not consumed preformed. The commercial paraxanthine supplement market is based on synthetic production rather than botanical extraction.

Related compounds: Caffeine, Theobromine, Theophylline, Methylliberine

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery